Article

Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy

2021-07-31

Abstract excerpt

<h4>Background</h4> In the U.S., more than 50% of ovarian cancer patients die within 5 years of diagnosis, highlighting the need for innovations such as engineered T cell therapies. Mesothelin (Msln) is an attractive immunotherapy target for this cancer, as it is overexpressed by the tumor and contributes to malignant and invasive phenotypes, making antigen loss disadvantageous to the tumor. We previously showed...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 522614f8-3883-57d2-a83d-af00798feafe
DOI: 10.1101/2021.07.30.454539

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacyDOI 10.1101/2021.07.30.454539Read

Mesothelin-Specific CAR T Cells Target Ovarian Cancer.Semantic proximity Read

Ligand-based adoptive T cell targeting CA125 in ovarian cancerSemantic proximity Read

Immunotherapy for ovarian cancer is improved by tumor-targeted delivery of a neoantigen surrogateSemantic proximity Read

Silencing of the TGF-β1 Gene Increases the Immunogenicity of Cells From Human Ovarian CarcinomaSemantic proximity Read

T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapySemantic proximity Read

Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape.Semantic proximity Read

Mannose receptor (MR) engagement by mesothelin GPI anchor polarizes tumor-associated macrophages and is blocked by anti-MR human recombinant antibody.Semantic proximity Read

CRISPR/Cas9-mediated TGFβRII Disruption Enhances Anti-tumor Efficacy of Human Chimeric Antigen Receptor T Cells in VitroSemantic proximity Read

Neutralizing PD-L1 and PD-L2 Enhances the Efficacy of Immune Checkpoint Inhibitors in Ovarian CancerSemantic proximity Read

Immune modulation of innate and adaptive responses restores immune surveillance and establishes anti-tumor immunological memorySemantic proximity Read

Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptorSemantic proximity Read

A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy.Semantic proximity Read